NCT01525173 - A Safety and Efficacy Study of ALPHAGAN® P and LUMIGAN® in Subjects Previously Treated With Latanoprost for Glaucoma and Ocular Hypertension | Biotech Hunter

Enrollment

137

Participants

Timeline

Start Date

January 31, 2012

Primary Completion Date

October 31, 2012

Study Completion Date

October 31, 2012

Conditions

GlaucomaOcular Hypertension

Interventions

DRUG

0.1% brimonidine tartrate ophthalmic solution

1 drop of 0.1% brimonidine tartrate ophthalmic solution 3 times per day for 12 weeks.

DRUG

0.01% bimatoprost ophthalmic solution

1 drop of 0.01% bimatoprost ophthalmic solution once per day for 12 weeks.

DRUG

0.2% hypromellose lubricant eye drops

1 drop of 0.2% hypromellose lubricant eye drops 3 times per day for 12 weeks.

DRUG

latanoprost 0.005% ophthalmic solution

1 drop of latanoprost 0.005% ophthalmic solution once daily as run-in therapy for 30 days only.

Trial Locations (1)

Deerfield Beach